Severe pemphigus foliaceus treated with extracorporeal photochemotherapy

Azana, J. M.

doi:10.1001/archderm.133.3.287

Cited by 7 publications

(7 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Extracorporeal photopheresis is known to have immunomodulatory effects and has been used in small numbers of patients with pemphigus; there are no RCTs. In a recent case series, eight patients with pemphigus were treated with two to six cycles of extracorporeal photopheresis, resulting in complete remission in all but one case.…”

Section: Extracorporeal Photopheresis (Strength Of Recommendation D mentioning

confidence: 99%

British Association of Dermatologists’ guidelines for the management of pemphigus vulgaris 2017

et al. 2017

View full text Add to dashboard Cite

show abstract

Section: Extracorporeal Photopheresis (Strength Of Recommendation D mentioning

confidence: 99%

British Association of Dermatologists’ guidelines for the management of pemphigus vulgaris 2017

et al. 2017

View full text Add to dashboard Cite

show abstract

“…Eleven patients with drug‐resistant, severe pemphigus (nine with pemphigus vulgaris and two with pemphigus foliaceus), who had cutaneous and mucous membrane involvement, underwent ECP . OR was 91% (10/11 patients), with 73% (8/11) having a CR, 18% (2/11) having a PR and 9% (1/11) having stable disease.…”

Section: Pemphigusmentioning

confidence: 99%

“…Prednisolone doses could be tapered in all patients . Three patients with recalcitrant foliaceus pemphigus who received ECP achieved one CR and two PRs . ECP was performed every 2–4 weeks for a minimum of two cycles, allowing the doses of combined therapies, including corticosteroids and immunosuppressants, to be tapered.…”

Section: Pemphigusmentioning

confidence: 99%

Guidelines on the use of extracorporeal photopheresis

Knobler

Berlin

Calzavara‐Pinton

et al. 2013

Acad Dermatol Venereol

183

206

View full text Add to dashboard Cite

BackgroundAfter the first investigational study on the use of extracorporeal photopheresis for the treatment of cutaneous T-cell lymphoma was published in 1983 with its subsequent recognition by the FDA for its refractory forms, the technology has shown significant promise in the treatment of other severe and refractory conditions in a multi-disciplinary setting. Among the major studied conditions are graft versus host disease after allogeneic bone marrow transplantation, systemic sclerosis, solid organ transplant rejection and inflammatory bowel disease.Materials and methodsIn order to provide recognized expert practical guidelines for the use of this technology for all indications the European Dermatology Forum (EDF) proceeded to address these questions in the hands of the recognized experts within and outside the field of dermatology. This was done using the recognized and approved guidelines of EDF for this task.Results and conclusionThese guidelines provide at present the most comprehensive available expert recommendations for the use of extracorporeal photopheresis based on the available published literature and expert consensus opinion.

show abstract

“…Since the first report on beneficial effects of adjuvant ECP in drug-resistant PV [18]several case reports have confirmed this positive observation [19–21] and extended the use of ECP to other autoimmune blistering diseases like pemphigus foliaceus [22, 23]. The treatment has also been applied to refractory epidermolysis bullosa acquisita with success [25, 26].…”

Section: Discussionmentioning

confidence: 98%

Short-Time Extracorporeal Photochemotherapy in the Treatment of Drug-Resistant Autoimmune Bullous Diseases

Wollina¹,

Lange²,

Looks³

1999

Dermatology

View full text Add to dashboard Cite

Background: Bullous pemphigoid (BP) and pemphigus vulgaris (PV) are potentially severe diseases. In drug-resistant PV and pemphigus foliaceus, long-term adjuvant treatment with extracorporeal photochemotherapy (photopheresis, ECP) has been reported to induce remission. Only limited numbers of patients have been reported so far. No information about the effectiveness in drug-resistant BP is available. Patients and Methods: Seven patients with drug-resistant autoimmune bullous diseases have been referred to the photopheresis center of Jena (3 × PV, 3 × BP, 1 × pemphigus foliaceus). The age ranged from 31 to 85 years. ECP was performed on 2 consecutive days once a month. Oral 8-methoxypsoralen was used as photosensitizer. Previous immunosuppressive treatment with either prednisolone or prednisolone/ azathioprine was continued. Results: Complete remission (absence of skin or mucous membrane lesions) was achieved in the 6 patients with PV and BP after 1–4 cycles. In the patient suffering from pemphigus foliaceus, a partial remission (> 50% improvement) was observed; in all except this patient, the immunosuppressive treatment could be tapered. Long-term remission was achieved. No severe side effects were observed. The treatment was well tolerated. Conclusions: Short-time ECP is an effective and safe adjuvant treatment for patients with drug-resistant autoimmune bullous diseases. It can induce remission and allows dose tapering of the immunosuppressive drugs.

show abstract

Severe pemphigus foliaceus treated with extracorporeal photochemotherapy

Cited by 7 publications

References 0 publications

British Association of Dermatologists’ guidelines for the management of pemphigus vulgaris 2017

British Association of Dermatologists’ guidelines for the management of pemphigus vulgaris 2017

Guidelines on the use of extracorporeal photopheresis

Short-Time Extracorporeal Photochemotherapy in the Treatment of Drug-Resistant Autoimmune Bullous Diseases

Contact Info

Product

Resources

About